Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Rapid FSME-IMMUN Schedule
NCT00161954Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2004
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of FSME-IMMUN in tick-borne encephalitis (TBE), sponsored by Pfizer. Primary endpoint: Seropositivity Rate (ELISA) at 14 days. Started Mar 2004; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00161954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161954.